Conversion of Securities

Iconic Labs PLC

02 November 2023

 

Iconic Labs PLC

("Iconic" or the "Company")

Conversion of Notes and Allotment of Shares

Iconic Labs PLC (LSE:ICON), announces that it has received a valid Conversion Notice from the European High Growth Opportunities Securitization Fund ("EHGO").

The Conversion Notice was dated 1 November 2023 and provides for 50 Convertible Notes to be converted into 500,000 ordinary shares of £0.1 in the Company ("Ordinary Shares") at a conversion price of £0.1 at the aggregate principal amount of £50,000.

The Conversion Notice also included a Conversion Fee, payable under the financing arrangements with EHGO, in the event that the price at 90% of the Lowest Closing Volume-Weighted Average Price during the applicable pricing period falls below the nominal value of the Ordinary Shares. The Conversion Fee has been satisfied by the issue to EHGO of an additional 522,490 Ordinary Shares.

Application is therefore being made for an aggregate of 1,022,490 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 8 November 2023. These shares rank pari passu with the existing Ordinary Shares of the Company.

Following the issue of these shares, the Company's issued ordinary share capital shall consist of 8,042,020 Ordinary Shares. The figure of 8,042,020 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For any further information or enquiries please contact:

[e-mail]

 

END